GW Pharmaceuticals unveils German pricing decision on Sativex

AIM-listed specialty pharmaceutical company GW Pharmaceuticals expects to account for a provision of 0.8m pounds in the financial year ending September 30th 2013 reflecting the impact of a pricing decision on its multiple sclerosis treatment Sativex.

AIM-listed specialty pharmaceutical company GW Pharmaceuticals expects to account for a provision of 0.8m pounds in the financial year ending September 30th 2013 reflecting the impact of a pricing decision on its multiple sclerosis treatment Sativex.

In an operational update issued on Tuesday, GW Pharmaceuticals stated: "For GW's financial year ended September 30th 2013, we expect to account for a provision of £0.8m to reflect the impact of this pricing decision, which we are required to apply to sales in Germany from July 2012, and product sales will be lower than previously expected. Cash and cash equivalents at December 31st 2012 was £27.6m."

In June 2012 the German Federal Joint Committee (G-BA), the national reimbursement authority, determined that Sativex - a plant-derived cannabinoid prescription drug - provided added benefit over current treatment options in the treatment of spasticity in multiple sclerosis.

After several months of discussions with the National Association of Statutory Health Insurance Funds, GW Pharmaceuticals' subsidiary Almirall said that it attended a meeting with an arbitration board to negotiate a price for Sativex.

The outcome of the meeting, which was communicated to Almirall on Tuesday, was the determination of a price "significantly lower than the reimbursed Sativex price in other European countries," the group reported.

Justin Gover, GW Pharmaceuticals' Chief Executive Officer, commented: "Sativex has an excellent record of achieving appropriate price levels in all other countries to date and we are confident that the ongoing global commercial prospects for Sativex outside of Germany are unchanged".

"Sativex is one of several examples of new medicines that have not been appropriately valued by the German reimbursement system. Almirall is now taking all necessary steps to maintain the success and value of the Sativex franchise across Europe."

GW Pharmaceuticals' share price was up 1.39% to 54.75p at 14:20 on Tuesday afternoon.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Inflation is the easiest way out of this – just don’t expect politicians to admit it
Inflation

Inflation is the easiest way out of this – just don’t expect politicians to admit it

The UK government borrowed £34.1bn in December, a record amount for that month. Britain's debt pile now amounts to 100% of GDP. How are we going to pa…
22 Jan 2021
When will the US stockmarket bubble burst?
US stockmarkets

When will the US stockmarket bubble burst?

With US stocks more expensive than before the Wall Street crash of 1929, there are growing signs of “mania”. But what will push markets over the edge?
22 Jan 2021